
Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials American Journal Of Clinical Dermatology

David M. Pariser,¹ Adelaide A. Hebert, Janice Drew, John Quiring, Ramanan Gopalan, Dee Anna Glaser


¹Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, dpariser@pariserderm.com

Supplemental Fig. 1 Study Design for ATMOS-1 and ATMOS-2 Trials



For subjects not enrolling in ARIDO, telephone follow-up occurred in Week 5 to record adverse events and concomitant medications. ^aGravimetrically-measured. ET, end of treatment for ATMOS-1 and ATMOS-2; GT, glycopyrronium tosylate; Wk, Week

Supplemental Fig. 2 ASDD Items 2, 3, and 4 at Baseline: Proportion of Patients at Different Threshold Score Cutoffs (Pooled Population)





ASDD, Axillary Sweating Daily Diary; ASDD-C, children's version of the ASDD (2 items); GT, glycopyrronium tosylate